VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant ...

Pfizer has terminated a Phase I trial of its investigational STING therapy in advanced solid tumors, according to an update ...

Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed ...

Pfizer (NYSE:PFE) is currently dealing with shareholder proposals concerning governance issues such as religious ...

The drug, vepdegestrant, failed to meaningfully delay cancer progression for all patients enrolled in the study but met its ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...

Arvinas (ARVN) and Pfizer (PFE) announced topline results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus ...

National rates of uterine rupture in trial of labor after cesarean increased from 0.20% in 2010 to 0.37% in 2022, with an ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.

and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial ...